The Convenience Myth in Drug Market Access
Everyone seems to win when a provider-administered drug requires fewer injections or shorter chair time. Patients enjoy fewer needle sticks and more freedom. Busy health systems free up infusion chairs. Staff members handle more patients each day. So payers should love the resulting cost savings — right?
Unfortunately, the reality disappoints patients, providers, and innovators alike. When products delivering greater ease of administration reach the market, payers rarely reward them with better coverage or premium pricing. Two real-world case studies reveal exactly why fewer needle sticks rarely move the needle on market access.
Case Study 1: Long-Acting Injectables for Eye Diseases
What the Data Shows About EYLEA HD
EYLEA (aflibercept) treats wet AMD and other serious eye diseases through intravitreal injection. Patients in the maintenance phase of dosing now have three choices:
- EYLEA — administered every 8 weeks
- EYLEA HD — administered every 8 to 16 weeks
- PAVBLU, an EYLEA biosimilar — administered every 8 weeks
On paper, EYLEA HD looks like the clear payer favorite. It delivers similar efficacy to EYLEA, yet it requires potentially half the injection frequency. Consequently, it reduces procedures, cuts patient visits, and lowers overall administrative burden. Furthermore, EYLEA HD carries the lowest WAC and ASP price when providers dose it every 16 weeks. Most observers would therefore expect EYLEA HD to enjoy premium access with fewer restrictions.
Why Payers Treat All Three Products Equally
That premium access never materializes. Across most major plans, all three aflibercept products receive identical prior authorization criteria. Despite clear convenience and cost-of-administration advantages for EYLEA HD, payers treat them all the same.
The math explains this outcome. Eliminating three to four intravitreal injection procedure fees each year saves Medicare less than $600. That figure simply does not compare meaningfully to the five-figure ophthalmology drug spend already on the table. Payers see no financial incentive to differentiate.
Case Study 2: Subcutaneous vs. IV Injections in Oncology
PHESGO and the SC Advantage
PHESGO combines the active ingredients in HERCEPTIN and PERJETA into a single subcutaneous formulation. This innovation transforms one or two lengthy IV infusions — typically requiring 60 to 150 minutes — into a 5-minute subcutaneous injection. Clinically, this is a genuine convenience superstar.
Because net prices based on ASP closely match the IV versions, some analysts expect payers to shift utilization toward PHESGO in order to save chair time and reduce staffing costs. Instead, payers grant PHESGO similar access to the IV products. They view the SC option as a treatment alternative, not a premium product that merits special positioning.
A Pattern Across Oncology Products
PHESGO is not an isolated case. The same pattern repeats across other IV-to-SC oncology products using hyaluronidase technology, including Opdivo QVANTIG, Herceptin HYLECTA, and Tecentriq HYBREZA. Annual costs remain similar across formulations, and access levels follow suit. Payers consistently view these as equivalent treatment alternatives rather than innovations deserving differentiated formulary status.
How Payers Really Calculate Administrative Burden
The Numbers Behind Administration Costs
The blunt truth is that less frequent or shorter administration rarely translates into better coverage or premium pricing. Administration costs are simply too small relative to specialty drug costs for payers to prioritize convenience. Consider these non-facility fee benchmarks from CMS:
- IV infusion (60 minutes): $50–$80
- Subcutaneous injection by healthcare provider: $10–$20
- Intravitreal injection: $100–$140
These figures are modest when compared to the five- and six-figure annual drug costs that dominate specialty pharmacy budgets.
Why Operational Savings Don’t Move Payers
Operational efficiencies from fewer or shorter infusions go to the health system, not the payer. Unless the health system is payer-owned — as with Kaiser Permanente — those savings belong to someone else entirely. Additionally, manufacturers often hold long-established contracts with payers. Both sides may find it unfavorable to disrupt those arrangements when a product reformulation enters the market. Instead, manufacturers and payers leave differentiation to prescribers and patients competing for market share.
In short, convenience is a clinical and operational win. However, it has not yet become a lever that reliably shifts payer behavior.
What Manufacturers Must Understand
Manufacturers bringing a new formulation, route, or dosing schedule to market must not assume that convenience will unlock premium access. Convenience may strengthen a payer value story, but net cost, contracting flexibility, and plan economics still dominate payer decision-making.
Moreover, manufacturers must frame their market access strategy around the payer’s financial perspective, not the patient’s clinical experience. Payers respond to data showing cost offsets that directly affect their budgets — not operational savings that accrue to hospital systems they do not own.
Key Takeaways
- Payers prioritize net drug cost over administrative convenience in formulary decisions.
- Administration cost savings are small relative to specialty drug spending and rarely influence coverage tiers.
- Operational efficiencies benefit health systems, not payers, in most plan structures.
- Manufacturers must align market access strategy with payer economics, not patient convenience metrics.
- Convenience adds value to the clinical story but does not independently justify premium pricing or preferred formulary status.
Understanding the payer calculus early in drug development helps manufacturers craft access strategies that reflect how coverage decisions actually get made — not how they should work in theory.
